Shares of Absci Corporation (NASDAQ:ABSI - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and eight have assigned a bu

VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the second quarter 2026 after market close on Tuesday, August 11, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) t

The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in ABSCI CORP (ABSI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Zen raised shares of Absci from a "sell" rating to a "hold" rating in a research report on Saturday.

Earlier this week, Absci Corporation reported encouraging interim Phase 1 data from its HEADLINE trial of ABS-201 for androgenetic alopecia, showing favorable safety, an estimated half-life of at least 65 days, and progression into a multiple ascending dose stage. On the heels of these results, Absci also completed a roughly US$100.00 million follow-on equity offering backed by Eli Lilly & Company and other institutional investors, underscoring external confidence in the ABS-201 program...

Shares of Absci Corporation (NASDAQ:ABSI - Get Free Report) have received a consensus rating of "Moderate Buy" from the nine ratings firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and eight have assi

ABSCI CORP (ABSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

No description provided for this story.

Eli Lilly is investing in a small startup developing a medication to spur hair growth, and potentially also treat endometriosis. The pharmaceutical giants behind the monumentally successful weight loss drugs Wegovy and Mounjaro have been teasing an expansion into other aesthetic fields like hair loss or skin care. Now, one of them is making a move, investing in a small startup developing a medication to spur hair growth, and potentially also treat endometriosis. On Wednesday, Absci announced that it raised $100 million from a group led by Eli Lilly. Lilly brought the lion’s share of the funding, handing over $40 million in exchange for equity in Absci, which is publicly traded on the Nasdaq. Continue to STAT+ to read the full story…

No description provided for this story.

Source: Bloomberg, 0:00 Hertz Global Holdings Inc Photographer: David Paul Morris/Bloomberg

Absci prices $100 million underwritten common stock offering at $7.41 per share to fund advancement of ABS-201Eli Lilly and leading institutional investors are participating in the underwritten common stock offering.Proceeds will also be used for general corporate purposes.Absci reports positive interim Phase 1 data from HEADLINE trial of ABS-201.

Analysts’ price target changes for Wednesday, June 24th: American Airlines Group (NASDAQ:AAL) had its price target increased by Jefferies Financial Group Inc. from $15.00 to $16.00. They currently have a hold rating on the stock. Absci (NASDAQ:ABSI) had its price target raised by BTIG Research from $9.00 to $13.00. BTIG Research currently has a buy […]

Absci (NASDAQ:ABSI – Get Free Report) had its price objective boosted by stock analysts at BTIG Research from $9.00 to $13.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research’s price objective would indicate a potential upside of 26.55% from the company’s previous close. […]

Absci, Tempus AI, and Hut 8 are the three Artificial Intelligence stocks to watch today, according to MarketBeat’s stock screener tool. Artificial intelligence stocks are shares of publicly traded companies that develop, use, or profit from AI technologies such as machine learning, data analytics, automation, and advanced computing. Stock market investors often view these companies […]

Related Stocks: ABSI,

No description provided for this story.

No description provided for this story.

Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci Proceeds from offering to support continued advancement of ABS-201™ across androgenetic alopecia and endometriosis VANCOUVER, Wash. and NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the pricing of

Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month period First multiple ascending dose (MAD) of ABS-201 in cohort of androgenetic alopecia (AGA) participants has been initiated Interim proof-of-concept data anticipated in the second half of 2026, with full proof-of-concept data in early 2

AI-driven drug discovery's rapid progression to human trials could revolutionize biotech timelines, potentially accelerating medical advancements. The post Absci Corporation progresses ABS-201 into human trials, bolstering AI-driven drug discovery appeared first on Crypto Briefing.

No description provided for this story.

Absci Corporation (NASDAQ:ABSI) has achieved a significant milestone in the biotech industry by moving an AI-designed antibody into a Phase 1 clinical trial. This accomplishment sets Absci apart as a leader in generative drug design and highlights the broader shift in biotech towards leveraging AI not only for modeling but also for practical drug creation. Explore how Absci’s unique integration of generative AI with experimental validation could affect the future of drug development.

No description provided for this story.

Absci, alongside MindWalk Holdings and a major AI compute provider, will participate in the Jones AI Day panel to discuss how AI-powered biological context and high-performance compute are reshaping drug discovery by addressing fragmented biological data and enabling trustworthy agentic AI in regulated workflows.

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones, alongside Absci (NASDAQ: ABSI) and a leading AI compute provider, as part of Jones AI Day. The panel, “Partnering to Power the New Era of Drug Discovery,” will be held on Monday, June 15, 2026, at 12:00 p.m. ET. Moderated by Jones Research Senior Research Analysts Dr.

No description provided for this story.

No description provided for this story.

Absci Corporation (NASDAQ:ABSI – Get Free Report) saw some unusual options trading activity on Friday. Traders acquired 11,273 call options on the stock. This represents an increase of approximately 403% compared to the typical volume of 2,241 call options. Insider Buying and Selling at Absci In other Absci news, insider Andreas Busch acquired 100,000 shares […]

Related Stocks: ABSI,

No description provided for this story.

No description provided for this story.

Royce & Associates LP reduced its position in Absci Corporation (NASDAQ:ABSI – Free Report) by 41.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 735,353 shares of the company’s stock after selling 526,080 shares during the quarter. Royce & Associates LP owned […]

A speculative but compelling AI biotech investment can be built around Absci and its attempt to rewire drug discovery itself.

Insiders who bought Absci Corporation ( NASDAQ:ABSI ) in the last 12 months may probably not pay attention to the...

No description provided for this story.

Absci Corporation (NASDAQ:ABSI - Free Report) - Equities researchers at HC Wainwright boosted their Q3 2026 EPS estimates for shares of Absci in a research report issued on Monday, May 11th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.22) per share for the quart

No description provided for this story.

Image source: The Motley Fool. DATEMay 7, 2026 at 4:30 p.m. ETCALL PARTICIPANTSFounder and Chief Executive Officer — Sean McClainChief Financial Officer and Chief Business Officer — Zach JonassonChief Medical Officer — Ronti SomerotneVice President, Investor Relations — Alex KhanTAKEAWAYSRevenue -- $200 thousand for the quarter, reflecting ongoing progress in partnered programs.Research and Development Expenses -- $19.3 million, rising from $16.4 million due to investment in internal programs and ABS-201 development.Selling, General, and Administrative Expenses -- $9.1 million, a reduction from $9.5 million, attributed to lower personnel costs.Cash, Cash Equivalents, and Marketable Securities -- $125.7 million at quarter end, compared to $144.3 million as of December 31, 2025.Runway -- Management projects sufficient funding into 2028 at current operating plans.ABS-201 Clinical Progress -- Phase 1/2a headline trial is on schedule; all single-ascending-dose cohorts completed, and initial multiple-ascending-dose cohort dosing begun.ABS-201 Safety -- "Emerging safety and tolerability data remain favorable," according to Chief Medical Officer Somerotne.ABS-201 Proof-of-Concept Data -- Preliminary safety, tolerability, and pharmacokinetics data expected next month, 13-week interim data in the second half of the year, and full 26-week readout projected early next year.Dosing Strategy -- Preliminary pharmacokinetic modeling supports a dosing interval of two or three injections spanning several months.Clinical Development Pathway -- Management indicates possible direct advancement from Phase 1/2a to registrational trials for androgenic alopecia, potentially accelerating timeline.ABS-201 Endometriosis Trial -- Phase 2 trial is targeted for initiation in the fourth quarter and supported by a new Clinical Advisory Board composed of academic leaders.ABS-202 Pipeline Expansion -- Announcement of ABS-202, an anti–prolactin receptor antibody, aimed at an undisclosed immunology and inflammation indication.Pipeline Prioritization -- Development for ABS-301 and ABS-501 is deprioritized, with no further company resources allocated.Market Opportunity: AGA -- Management market research suggests a potential U.S. total available market over $25 billion annually, with the proposed ABS-201 dosing profile.Market Opportunity: Endometriosis -- Company estimates prevalence at 9 million U.S. women, with potential peak sales for ABS-201 over $4 billion.Consumer Demand Metrics -- Survey responses report "87% of men, and 69% of women [are] extremely or very likely" to seek out ABS-201; figures increase to "92% for men, and 89% for women" among standard-of-care users.Agentic AI Implementation -- Management states "meaningful efficiency gains" already observed from broad adoption of agentic AI workflows across all major functional areas.Need a quote from a Motley Fool analyst? Email pr@fool.comRISKSNone cited with explicit negative consequences or adverse data during the earnings call.SUMMARYAbsci Corporation (NASDAQ:ABSI) reported continued clinical and financial discipline, highlighted by on-track advancement of ABS-201 in androgenic alopecia and plans to begin a Phase 2 trial for endometriosis later in the year. Management highlighted shifting strategic focus: resources will be directed away from ABS-301 and ABS-501, while the prolactin-based portfolio expands with ABS-202 for immunology and inflammation. The company plans to leverage agentic AI adoption for additional cost savings and operational scalability as clinical milestones approach. No adverse clinical signals or operational weaknesses were referenced that would indicate material near-term risk for ongoing programs.Management’s forecasts place cash sufficiency through major clinical catalysts, and into 2028, reducing immediate financing concerns.Upcoming readouts—preliminary ABS-201 safety data, 13-week interim efficacy, and 26-week full proof-of-concept—set the cadence for market-moving data events in 2026 and early 2027.ABS-201’s clinical path may support an accelerated registrational strategy depending on upcoming data and regulatory interaction.Patient and physician survey data indicate both high unmet need, and pronounced willingness to adopt a product profile such as ABS-201’s, strengthening the implied commercial case.INDUSTRY GLOSSARYPhase 1/2a: An early-stage clinical trial combining initial human safety evaluation (Phase 1) with preliminary efficacy and dosing studies (Phase 2a).SAD and MAD: Single-Ascending-Dose (SAD) and Multiple-Ascending-Dose (MAD) clinical study cohorts used to characterize safety and pharmacokinetics.PK: Pharmacokinetics—the study of how a drug is absorbed, distributed, metabolized, and eliminated in the body.POC: Proof-of-concept—the stage at which data are sufficient to suggest efficacy for the intended indication.TPP: Target Product Profile—a strategic summary of the intended characteristics and performance of a drug in clinical development.Agentic AI: AI workflows capable of autonomous decision-making and task execution, referenced as cost/capability multipliers in the call.Full Conference Call TranscriptAlex Khan: Absci Corporation released financial and operating results for the quarter ended 03/31/2026. If you have not received this news release, or if you would like to be added to the company’s distribution list, please send an email to investorsasci.com. An archived webcast of this call will be available for replay on Absci Corporation's Investor Relations website at investors.avsci.com for at least 90 days after this call. Joining me today are Sean McClain, Absci Corporation's Founder and CEO; Zach Jonasson, Chief Financial Officer and Chief Business Officer; and Ronti Somerotne, Chief Medical Officer. Before we begin, I would like to remind you that management will make statements during the call that are forward-looking within the meaning of the federal securities laws.These statements involve material risks and uncertainties that could cause results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements.These include statements regarding the development and clinical progress of our pipeline programs, including ABS-201; the design, enrollment, product, and timelines of our ongoing Phase 1/2a headline trial of ABS-201 in androgenic alopecia; anticipated timing of interim proof-of-concept data readout for ABS-201 in 2026; the potential advancement of ABS-201 into Phase 3 development; anticipated initiation of a Phase 2 clinical trial of ABS-201 for endometriosis in 2026, and a potential proof-of-concept readout in 2027; the anticipated characteristics and product profile of ABS-201 as a drug product; our target product profile and its attributes; the potential for an expedited development pathway, including the possibility of advancing directly from Phase 1/2a into Phase 3; our plan to engage with the FDA regarding development strategy; and the potential market opportunity and commercial prospects for ABS-201.Certain statements may also include projections regarding potential market opportunity. These estimates are based on various assumptions, including potential regulatory approval, the final approved label, and the evolving competitive landscape, any of which could cause our actual addressable market to differ materially from these projections. In addition, certain research findings discussed today reflect participant responses to a hypothetical product profile and do not represent clinical results for ABS-201. Additional information regarding the risks and uncertainties that could affect our forward-looking statements is set forth in the press release Absci Corporation issued today, our most recent annual report on Form 10-K, subsequent documents, and reports filed by Absci Corporation from time to time with the SEC.Except as required by law, Absci Corporation disclaims any intent or obligation to update or revise any financial or product pipeline projections or other forward-looking statements because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast on 05/07/2026. With that, I will turn the call over to Sean.Sean McClain: Good afternoon, everyone. Thanks for joining us. Today, I will cover three things: where we are on ABS-201, a new addition to our prolactin pipeline, and the strategy driving both. 2026 is going to be a data-rich year for Absci Corporation with multiple readouts in front of us. Ronti will go through the headline trial and discuss early PK modeling that supports our targeted dosing frequency. At a high level, the Phase 1/2a is on track. We expect to share preliminary safety, tolerability, and PK data next month; interim 13-week hair regrowth data in the second half of this year; and full 26-week proof-of-concept data early next year. ABS-201 is not intended to compete with minoxidil.We are aiming to create a new category of hair regrowth therapy—a targeted biologic against the prolactin receptor that provides durable hair regrowth from a few injections. If successful, ABS-201 could represent the first new mechanism of action in androgenic alopecia in nearly three decades and a fundamentally different treatment paradigm for patients. In parallel, we continue to advance towards initiation of a Phase 2 endometriosis trial in the fourth quarter. We recently launched our endometriosis Clinical Advisory Board with leaders from Yale, UCSF, Duke, and Mayo Clinic. They bring deep expertise across reproductive medicine, fertility, and translational research and will help guide ABS-201’s endometriosis program.Endometriosis has the same kind of opportunity as AGA—large, underserved, and underexplored—and ABS-201 has the potential to open up a new category of therapy there as well. As Zach will discuss, our top strategic prio

Absci (NASDAQ:ABSI) executives on Wednesday outlined a “data-rich” 2026 anchored by multiple clinical updates for ABS-201, the company’s anti-prolactin receptor antibody being studied in androgenetic alopecia (AGA), and plans to expand a broader prolactin-focused pipeline with a newly disclosed prog

No description provided for this story.

No description provided for this story.

No description provided for this story.

Absci Corporation (NASDAQ:ABSI – Get Free Report) shares hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $5.25 and last traded at $5.1950, with a volume of 1408079 shares changing hands. The stock had previously closed at $4.92. Wall Street Analyst Weigh In Several analysts have commented […]

No description provided for this story.

Related Stocks: ABSI,

Absci (NASDAQ:ABSI) Hits New 1-Year High - Time to Buy?

Absci (NASDAQ:ABSI) Sees Large Volume Increase - Still a Buy?

No description provided for this story.

Absci Corp. (NASDAQ:ABSI) is one of the 10 most shorted penny stocks to buy. As of the April 23 closing, the stock carries a strongly bullish consensus sentiment. Of the 7 analysts who provided coverage, 6 assigned Buy ratings and 1 gave a Hold call. It has a median 1-year target price of $7.64, leading […]